OnKure Therapeutics, Inc.

NASDAQ:OKUR

Biotechnology

Healthcare
$2.82 +0.23%

+$0.01 today

Market cap
$114.22M
Beta
0.28
P/E (TTM)
-1.0
EPS (TTM)
-$4.30
52W Low $1.91High $5.38

Volume 0.17M

Average 0.37M

OKUR Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

OnKure Therapeutics, Inc.NASDAQ: OKUR

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $15.41M fell 9.3% year over year, ahead of the -12.1% change in trailing-twelve-month operating expenses. Sequentially, it rose 9.1% from the prior quarter. Over 3 fiscal years it compounded at +27.8% a year.

Context

  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -9.3% holds above the trailing-twelve-month pace of -12.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.41M+9.1% QoQ
Last fiscal yearDec 2025
$62.12M+14.2% YoY
LTMMar 2026
$61.36M-12.1% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.3%——
1 year+14.2%——
3-year CAGR+27.8%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
62.12M USD
Year-over-year change
+14.2%
4-year CAGR
+11.8%

Operating Expenses vs competitors

How OKUR compares with its peers on the latest reported figures

  • OKUR's LTM Mar 2026 operating expenses of $61.36M is the 2nd highest of the 4 companies compared; the peer median is $28.96M.
  • Its year-over-year change of -12.1% is the 2nd highest of 4, against a peer median of -18.0%.
  • Over three fiscal years its annual growth of +27.8% compares with a peer median of -1.9%.
OKUR Competitors Peer median
Operating Expenses for OKUR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XLOXilio Therapeutics, Inc.LTM Mar 2026$80.05M +20.9%-1.9%149.7%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$61.36M -12.1%+27.8%—
PDSBPDS Biotechnology CorporationLTM Mar 2026$28.96M -18.0%-8.9%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$25.93M -40.9%+1.1%73.9%
Peer median (excluding OKUR) $28.96M-18.0%-1.9%111.8%

Competitors are the stored peer set for OKUR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue50K000830K
Gross Profit(50K)000(830K)
Gross Margin—————
Research & Development28.12M25.86M32.12M43.8M48.26M
Selling, General & Admin11.65M3.9M4.82M10.59M14.69M
Operating Expenses39.77M29.77M36.93M54.39M62.12M
Depreciation & Amortization50K387K560K662K830K
EBITDA(39.72M)(29.13M)(34.75M)(51.71M)(58.69M)
EBITDA Margin—————
Operating Income(39.82M)(29.77M)(36.93M)(54.39M)(62.95M)
Operating Margin—————
Interest Income0254K1.62M2.01M3.44M
Interest Expense000300K0
Other Income / Expenses48K254K1.62M1.71M3.43M
Income Before Tax(39.77M)(29.51M)(35.31M)(52.67M)(59.52M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(39.77M)(29.51M)(35.31M)(52.67M)(59.52M)
Net Margin—————
EPS (Basic)(21.92)(2.21)(2.65)(3.95)(4.40)
EPS (Diluted)(21.92)(2.21)(2.65)(3.95)(4.40)
Weighted Avg Shares1.81M13.34M13.34M13.34M13.52M
Weighted Avg Shares (Diluted)1.81M13.34M13.34M13.34M13.52M

OnKure Therapeutics, Inc.

NASDAQ:OKUR

Intrinsic Alpha fair value

Locked

Current Price

$2.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.